Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs

Infection Control and Hospital Epidemiology

Volumn 24, Issue 4, 2003, Pages 251-256

  Song, Xiaoyan ^a,c   Srinivasan, Arjun ^a   Plaut, David ^a   Perl, Trish M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; SAMPLE SIZE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CROSS INFECTION; FEMALE; HOSPITAL CHARGES; HOSPITAL MORTALITY; HOSPITALS, TEACHING; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VANCOMYCIN RESISTANCE;

EID: 0037847608     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502196     Document Type: Article

References (22)

1. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439-442.
2. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993. MMWR 1993;42:597-599.
3. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
4. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998;104:1S-2S.
5. Linden PK, Miller CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 1999;33:113-120.
6. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145-158.
7. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-1239.
8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
9. 3M Health Information Systems. All Patient Refined-Diagnosis Related Groups Definitions Manual, version 15.0. St. Paul, MN: 3M Health Information Systems; 1998.
10. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127-1133.
11. Beltrami EM, Singer DA, Fish L, et al. Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreak. Am J Infect Control 2000;28:282-285.
12. Brown AR, Amyes SG, Paton R, et al. Epidemiology and control of vancomycin-resistant enterococci (VRE) in a renal unit. J Hosp Infect 1998;40:115-124.
13. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997;132:76-81.
14. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-323.
15. Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden for the hospital. Am J Med 1991;16:145S-151S.
16. Bhorade SM, Christenson J, Pohlman AS, Arnow PM, Hall JB. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999;115:1085-1091.
17. Stosor V, Peterson LR, Postelnick M, Noskin GA Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-527.
18. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci U S A 1999;96:6908-6913.
19. Dembek ZF, Kellerman SE, Ganley L, et al. Reporting of vancomycin-resistant enterococci in Connecticut: implementation and validation of a state-based surveillance system. Infect Control Hosp Epidemiol 1999;20:671-675.
20. Srinivasan A, Song XS, Brower R, Perl MT. Gowns and gloves precautions versus gloves alone in preventing transmissions of vancomycin resistant enterococci (VRE) in an ICU. Presented at the 38th Annual Meeting of the Infectious Diseases Society of America; September 7-10, 2000; New Orleans, LA.
21. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(RR12):1-13.
22. Morgan AS, Brennan PJ, Fishman NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970-973.